This Phase 2 research met its principal endpoint.
UCB and Amgen Announce Positive Phase 2 Results of AMG 785/CDP7851 Amgen and UCB announced positive top-line results from their Phase 2 clinical research comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal females with low bone mineral density for the treating postmenopausal osteoporosis silagra 100 . This Phase 2 research met its principal endpoint, demonstrating significant boosts in lumbar backbone bone mineral density at month 12 for the AMG 785/CDP7851 active hands versus the placebo arm. Furthermore, AMG 785/CDP7851 weighed against both active comparators positively, teriparatide and alendronate. The entire incidence of adverse events was generally well balanced between groups.
The study, which began taking form in 2007, was funded by Church & Dwight Co., the maker of Trojan condoms. Queries about condom usage figured prominently in the analysis, but the researchers – during a teleconference – insisted the integrity of their findings was not affected by the corporate tie. Among the findings was a higher rate of condom usage among 14 – to 17-year-olds. Of the surveyed males who had sexual intercourse, 79 % reported utilizing a condom on the newest occasion, compared to twenty five % for all the men in the survey. However, the sample for that one question involved only 57 teens in the 14-to-17 a long time. That’s far smaller compared to the thousands involved in latest federal government Youth Risk Behavior Study last year which calculated condom use among sexually active high school students at 61 % Fortenberry nonetheless found the brand new findings encouraging.